DK1332137T3 - Behandling af gastrointestinale stromale tumorer - Google Patents

Behandling af gastrointestinale stromale tumorer

Info

Publication number
DK1332137T3
DK1332137T3 DK01988712T DK01988712T DK1332137T3 DK 1332137 T3 DK1332137 T3 DK 1332137T3 DK 01988712 T DK01988712 T DK 01988712T DK 01988712 T DK01988712 T DK 01988712T DK 1332137 T3 DK1332137 T3 DK 1332137T3
Authority
DK
Denmark
Prior art keywords
treatment
gastrointestinal stromal
stromal tumors
methylpiperazin
ylamino
Prior art date
Application number
DK01988712T
Other languages
Danish (da)
English (en)
Inventor
David Tuveson
Renaud Capdeville
Brian J Druker
Elisabeth Buchdunger
Sandra Leta Silberman
Michael C Heinrich
George Daniel Demetri
Sasa Dimitrijevic
Jonathan A Fletcher
Heikki Joensuu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1332137(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1332137T3 publication Critical patent/DK1332137T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
DK01988712T 2000-10-27 2001-10-26 Behandling af gastrointestinale stromale tumorer DK1332137T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27

Publications (1)

Publication Number Publication Date
DK1332137T3 true DK1332137T3 (da) 2006-07-17

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01988712T DK1332137T3 (da) 2000-10-27 2001-10-26 Behandling af gastrointestinale stromale tumorer

Country Status (25)

Country Link
US (1) US6958335B2 (https=)
EP (1) EP1332137B1 (https=)
JP (1) JP4386635B2 (https=)
KR (1) KR100885129B1 (https=)
CN (1) CN1276754C (https=)
AT (1) ATE321556T1 (https=)
AU (2) AU1826202A (https=)
BR (1) BRPI0114870B8 (https=)
CA (1) CA2424470C (https=)
CY (1) CY1105055T1 (https=)
CZ (1) CZ303944B6 (https=)
DE (1) DE60118430T2 (https=)
DK (1) DK1332137T3 (https=)
ES (1) ES2260317T3 (https=)
HU (1) HU229106B1 (https=)
IL (2) IL155029A0 (https=)
MX (1) MXPA03003703A (https=)
NO (1) NO324948B1 (https=)
NZ (1) NZ525254A (https=)
PL (1) PL209733B1 (https=)
PT (1) PT1332137E (https=)
RU (1) RU2301066C2 (https=)
SK (1) SK287335B6 (https=)
WO (1) WO2002034727A2 (https=)
ZA (1) ZA200302155B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2444867C (en) * 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
ES2266553T3 (es) * 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
WO2003003006A2 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
US20040266797A1 (en) * 2001-06-29 2004-12-30 Alain Moussy Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
ES2274993T3 (es) * 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
JP2004537542A (ja) * 2001-06-29 2004-12-16 アブ サイエンス 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用
EP1461032B1 (en) * 2001-09-20 2008-07-16 AB Science Use of c-kit inhibitors for promoting hair growth
EP1427379B1 (en) * 2001-09-20 2008-08-13 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
DE60307237T2 (de) * 2002-02-27 2007-10-18 Ab Science Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
CA2538523A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
WO2007089716A2 (en) * 2006-02-01 2007-08-09 The Regents Of The University Of California Use of aminopyrimidine compounds in the treatment of immune disorders
AU2007296743B2 (en) * 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
WO2008033747A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2012122058A2 (en) 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US20160015708A1 (en) 2012-02-21 2016-01-21 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP6464084B2 (ja) 2012-07-27 2019-02-06 イズミ テクノロジー，エルエルシー 排出阻害剤およびこれを用いる治療法
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2019016673A2 (en) 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
US12186393B2 (en) 2019-08-02 2025-01-07 Onehealthcompany, Inc. Method of treating transitional cell carcinoma in a canine by administering lapatinib, wherein the carcinoma harbors a BRAF mutation
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4013412B1 (en) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
EP4084779B1 (en) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528449A1 (ru) * 1985-06-05 1989-12-15 Центральный институт усовершенствования врачей Способ релаксации илеоцекального отдела кишечника
TW225528B (https=) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP2002523455A (ja) * 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体

Also Published As

Publication number Publication date
IL155029A (en) 2009-09-22
EP1332137A2 (en) 2003-08-06
AU1826202A (en) 2002-05-06
CZ20031152A3 (en) 2004-04-14
CA2424470A1 (en) 2002-05-02
JP2004512328A (ja) 2004-04-22
ES2260317T3 (es) 2006-11-01
HU229106B1 (en) 2013-07-29
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
CN1622808A (zh) 2005-06-01
KR20030051656A (ko) 2003-06-25
BRPI0114870B8 (pt) 2021-05-25
WO2002034727A2 (en) 2002-05-02
NO20031833L (no) 2003-04-24
EP1332137B1 (en) 2006-03-29
SK5182003A3 (en) 2004-02-03
US20040023976A1 (en) 2004-02-05
CA2424470C (en) 2009-06-09
KR100885129B1 (ko) 2009-02-23
CY1105055T1 (el) 2010-03-03
RU2301066C2 (ru) 2007-06-20
PL362148A1 (en) 2004-10-18
NZ525254A (en) 2006-02-24
BR0114870A (pt) 2004-02-17
AU2002218262B2 (en) 2005-09-29
DE60118430D1 (de) 2006-05-18
MXPA03003703A (es) 2005-01-25
HK1058193A1 (en) 2004-05-07
ATE321556T1 (de) 2006-04-15
IL155029A0 (en) 2003-10-31
SK287335B6 (sk) 2010-07-07
ZA200302155B (en) 2004-04-22
NO324948B1 (no) 2008-01-07
BRPI0114870B1 (pt) 2020-06-16
CZ303944B6 (cs) 2013-07-10
JP4386635B2 (ja) 2009-12-16
DE60118430T2 (de) 2006-10-26
PL209733B1 (pl) 2011-10-31
HUP0301512A2 (hu) 2003-11-28
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
CN1276754C (zh) 2006-09-27

Similar Documents

Publication Publication Date Title
DK1332137T3 (da) Behandling af gastrointestinale stromale tumorer
TR200000060T2 (tr) Bir N-fenil-2-pirimidinamin türevinin kristal modifikasyonu ve yapım işlemleri ve kullanımı.
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
DK1471916T3 (da) Behandling af rheumatoid arthritis under anvendelse af imatinib
BR0316126A (pt) Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica
AU2003216621A8 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
NO20056188L (no) Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
DE60305460D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
WO2004103374A3 (en) Imatinib combinations for head and neck cancers
HK1097535A (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide